COVID-19

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Updated March 27, 2020 (original story follows) Editor’s note: It’s been just over one month since we first shared how established relationships have helped our organization navigate the impacts of the coronavirus on the cell therapy supply chain. Since then, much has changed. Just a few days after we posted the story, reports from Italy…

HLA matching could bring more allogeneic cell therapies to market, faster

The emergence of novel cell therapy technologies has led to questions about the necessity of human leukocyte antigen matching (HLA matching) in the development of potential “universal” allogeneic cell therapies. After all, if you can eliminate alloreactive responses, what role would HLA matching play? Martin Maiers, MS, is the Vice President of Biomedical Informatics for…

How to overcome 3 common cell therapy supply chain disruptions

One patient, one product. The successful on-time delivery of cell and gene therapies isn’t just good business—it’s a matter of survival for patients. When there’s no room for mistakes, an advanced approach is needed to overcome supply chain disruptions that create barriers to successful on-time delivery. Severe weather, customs complexities and flight delays are three…

Abby McDonald, PhD, is the manager of Solutions Development at Be The Match BioTherapies

Driving CAR-T therapy safety and sustainability for the road ahead

Autologous and allogeneic CAR-T therapies continue to hold significant promise for patients. But with that potential comes challenges, as more CAR-T therapies enter clinical trials and commercialization. Some are universal to both autologous CAR-T and allogeneic CAR-T, but each has its unique obstacles, too. Abby McDonald, PhD, supervises the Solutions Development team for Be The…